Abstract
BackgroundAcral lentiginous melanoma (ALM), a cutaneous melanoma subtype, exhibits a poorer prognosis than non-acral cutaneous melanoma (NACM). The neutrophil-to-lymphocyte ratio (NLR) is emerging as a prognostic indicator across diverse cancers. ObjectiveWe explored the baseline NLR disparities between ALM and NACM, and the NLR’s prognostic significance in patients with ALM. MethodsWe reviewed records of patients with ALM and NACM diagnosed between 1997 and 2022, analyzing medical data. ResultsAmong 327 and 159 patients with ALM and NACM, respectively, baseline NLR varied based on distinct clinicopathological factors between ALM and NACM. In stage 3–4 melanomas, the median NLR for ALM (2.18; interquartile range, 1.70–3.08) significantly surpassed NACM (1.74; interquartile range, 1.33–2.53) (P=0.029). In patients with ALM, high NLR (hazard ratio, 1.64; 95% confidence interval, 1.02–2.66; P=0.043) was independently correlated with poor progression-free survival when adjusting for ulceration, Breslow thickness ≥2 mm, and nodal invasion. LimitationsSingle-center, retrospective design. ConclusionAdvanced-stage ALM exhibited a significantly higher baseline NLR compared to that of NACM. Evaluating baseline NLR could provide valuable prognostic insights for patients with ALM.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callSimilar Papers
More From: Journal of the American Academy of Dermatology
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
